ABSTRACT
AIM: It is well known that vitamin D plays an important role in maintaining bone homeostasis and in regulating calcium absorption. The active form of vitamin D interacts with its receptor the VDR that is expressed in multiple tissues and it is involved in platelets (PLTs) function. In the present study we evaluate PLTs' VDR expression in osteoporotic as opposed to healthy subjects. METHODS: We enrolled in the study 77 women with postmenopausal osteoporosis, 33 healthy women of childbearing age, 49 healthy men, and 11 healthy women matched with patients for age and postmenopausal period. Thirty-nine patients had had one femoral fracture occurred after the age of fifty and attributable to primary osteoporosis. Bone mineral density, markers of bone metabolism and VDR levels were measured in all the subjects. RESULTS: Our data show that VDR level is lower in patients as respect to controls and is positively correlated with bone density, but not with markers of bone metabolism. We also found a decrease in the phosphorus levels in patients without differences in vitamin D levels and in the dietary calcium intake. CONCLUSION: The lower VDR expression in osteoporotic could indicate a lower ability to respond to vitamin D, and could be the explanation of the increase in the PTH and decrease in the phosphorus levels in patients with respect to controls.
Subject(s)
Blood Platelets/cytology , Osteoporosis/metabolism , Receptors, Calcitriol/metabolism , Vitamin D/metabolism , Adult , Aged , Blood Platelets/metabolism , Bone Density , Bone and Bones/metabolism , Dose-Response Relationship, Drug , Female , Femoral Fractures/metabolism , Humans , Male , Middle Aged , Phosphorus/metabolismABSTRACT
Chronic renal insufficiency (CRI) causes important modifications in the metabolism of phosphorus and calcium, to which frequently resulting in serious disorders of the skeleton, including demineralization, reduction of the bone resistance and a higher risk of fractures. Renal osteodystrophy is the term used to describe these disorders; they are generally heterogeneous and are classified according to the state of bone turnover into secondary hyperparathyroidism, adynamic bone, and osteomalacia. The incidence of hip fractures in the patients with CRI is higher than in the general population. Hip fractures are an important cause of morbidity and mortality. The evaluation of the fracture risk in the patients with different degrees of CRI is problematic, in particular because of the difficulty in identifying fractures, especially vertebral ones. The instrumental index that best expresses the fracture risk in the general population is bone mineral density (BMD); however, the relationship between low BMD and CRI is disputed. Bone disorders in patients with CRI have in fact a multifactorial pathogenesis and low BMD is not the only risk factor for fractures. Besides densitometric evaluation, also that vertebral morphometric evaluation would be desirable in patients with CRI. The fracture risk increases progressively with the severity of chronic renal disease and it is especially high in patients with renal insufficiency in more advanced-stages CRI (creatinine clearance<15-20 mL/min). However, not only in patients with severe CRI undergoing dialysis, but also in those with milder renal disease is the risk of bone fractures high.
Subject(s)
Fractures, Spontaneous/etiology , Kidney Failure, Chronic/complications , Absorptiometry, Photon , Age Factors , Aged , Bone Demineralization, Pathologic/etiology , Bone Demineralization, Pathologic/metabolism , Bone Density , Bone Remodeling , Calcium/metabolism , Chronic Kidney Disease-Mineral and Bone Disorder/etiology , Chronic Kidney Disease-Mineral and Bone Disorder/metabolism , Female , Fractures, Spontaneous/epidemiology , Fractures, Spontaneous/metabolism , Hip Fractures/epidemiology , Hip Fractures/etiology , Hip Fractures/metabolism , Humans , Hyperparathyroidism, Secondary/etiology , Hyperparathyroidism, Secondary/metabolism , Incidence , Kidney Failure, Chronic/metabolism , Male , Osteomalacia/etiology , Osteomalacia/metabolism , Phosphorus/metabolism , Risk , Spinal Fractures/epidemiology , Spinal Fractures/etiology , Spinal Fractures/metabolismABSTRACT
UNLABELLED: None of the available osteoporosis therapies completely abolish the risk of fracture. Among 862 patients on treatment with antiresorptive agents (alendronate, risedronate, and raloxifene) for >1 year a fragility fracture was observed in 9.5%/year. This incidence is considerably higher than that observed in randomized clinical trials. INTRODUCTION: Available osteoporosis therapies reduced in randomized controlled trials (RCTs) the risk of fracture by 30-50%. The proportion of patients suffering from new fractures while on active treatment ("inadequate clinical treatment response" or ICR) can be derived from the data of the RCTs, where confounding factors are usually controlled by the exclusion criteria. In the retrospective part of the ICARO study we observed a 8.9% annual incidence of ICR. Here we report the results of the longitudinal part of the study. METHODS: The study includes 862 women with severe postmenopausal osteoporosis. Ninety-two of these patients (10.7%) were defined as having ICR (9.5%/year) during therapy with antiresorptive drugs (alendronate, risedronate, and raloxifene) for at least 1 year. RESULTS: The ICR patients were comparable to patients who did not sustain clinical fractures with regard to body mass index, follow-up duration, number of prevalent vertebral fractures, type of osteoporosis treatment, proportion of patients taking calcium and vitamin D supplements, and compliance with treatment. Those with ICR were significantly older (p=0.032) and more frequently had multiple vertebral deformities (p=0.013). CONCLUSIONS: The incidence of ICR during treatment with antiresorptive agents among patients with severe postmenopausal osteoporosis in a routine setting is considerably higher than that observed in randomized clinical trials.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Fractures, Bone/etiology , Osteoporosis, Postmenopausal/complications , Osteoporosis, Postmenopausal/drug therapy , Adult , Age Factors , Aged , Alendronate/therapeutic use , Body Mass Index , Etidronic Acid/analogs & derivatives , Etidronic Acid/therapeutic use , Female , Fractures, Bone/epidemiology , Fractures, Bone/prevention & control , Humans , Italy/epidemiology , Longitudinal Studies , Middle Aged , Osteoporosis, Postmenopausal/epidemiology , Raloxifene Hydrochloride/therapeutic use , Risedronic Acid , Treatment FailureABSTRACT
Some studies have suggested that hypovitaminosis D may be a consequence of protein-calorie malnutrition. This study assessed both the relationship between vitamin D status, malnutrition, calcium and phosphorus metabolism indices and the importance attached by internists to these alterations. There were 239 patients admitted to an internal medicine division who underwent examinations to assess nutritional state, liver and renal function, and bone metabolism. At the end of the study, the clinical data included in the discharge letter, the treatment prescribed, and the diagnosis assigned to patients on their hospital discharge form were collected. Hypovitaminosis D was found in 72% and hypoalbuminemia in 34.3% of patients. Subjects with hypovitaminosis were generally older and had lower albumin levels than those with mild or no hypovitaminosis. 25-Hydroxyvitamin D was inversely related with parathyroid hormone and directly related with albumin. Alterations of calcium and phosphorus metabolism were present in 55.6% and recorded by the division's physicians for only 13.53% of patients, of whom 72.37% were not specifically treated. There is a direct correlation between 25-hydroxyvitamin D and albumin levels. The high incidence and the metabolic consequence of hypovitaminosis D and of protein-calorie malnutrition is significantly underestimated and undertreated by physicians.
Subject(s)
Inpatients , Internal Medicine , Vitamin D Deficiency/epidemiology , Aged , Aged, 80 and over , Calcium/metabolism , Female , Humans , Male , Middle Aged , Phosphorus/metabolism , Protein-Energy Malnutrition/blood , Protein-Energy Malnutrition/epidemiology , Protein-Energy Malnutrition/metabolism , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/metabolismABSTRACT
In a randomized multicenter, double-blind, double-dummy, parallel group study a comparison of the efficacy and safety of 1 microg alfacalcidol to 880 IU vitamin D plus calcium carbonate (1 g calcium) once daily per os was performed on 148 postmenopausal osteoporotic Caucasian patients with normal vitamin D serum levels for 18 months. Bone mineral density (BMD) was measured at baseline, 12 and 18 months. Safety parameters were followed during the entire study period. Sixty-nine (90.8%) in the alfacalcidol group and 67 (93.1%) in the vitamin D group were included in the ITT analysis. Lumbar BMD in the alfacalcidol group increased by 0.017 g/cm2 (2.33%) and 0.021 g/cm2 (2.87%) from baseline (P<0.001) at 12 and 18 months, respectively, whereas in the vitamin D plus calcium group the increase was 0.005 g/cm2 (0.70%) from baseline (N.S.) at both 12 and 18 months. The higher changes from baseline in the alfacalcidol group, as compared to the changes in the vitamin D plus calcium group at both 12 and 18 months, were found to be statistically significant (P=0.018, 0.005). A small increase of mean femoral BMD was achieved in both groups (N.S.). Adverse events were similar in both groups. No significant differences were noted between the groups in serum calcium. In conclusion, alfacalcidol was found to be superior in significantly increasing lumbar BMD as compared to vitamin D plus calcium while safety characteristics were found to be similar in both treatments.
Subject(s)
Bone Density Conservation Agents/therapeutic use , Bone Density/drug effects , Calcium Carbonate/therapeutic use , Hydroxycholecalciferols/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Vitamin D/therapeutic use , Aged , Dietary Supplements , Double-Blind Method , Drug Therapy, Combination , Female , Humans , Lumbar Vertebrae/drug effects , Middle AgedABSTRACT
Western diets rich in animal protein result in long-term acid loading that, despite corresponding increases in net renal acid excretion, may induce a chronic state of acidemia. This may have deleterious effects on both the kidney and bone, by increasing the risk of calcium stone in the former and leading to chemical dissolution of mineral alkaline salts in the latter. Whereas supplementation with alkaline citrate has been shown to reduce stone recurrences, its effect on bone turnover has received less attention. The aim of the present study was to evaluate whether potassium citrate favorably affects bone turnover markers in postmenopausal females with low bone density. Thirty women, aged 58 +/- 8.1 years, were enrolled and studied on basal conditions and after a 3-month course of potassium citrate supplementation (0.08-0.1 g/kg b.w. daily). Twenty-two women concluded the study while 8 withdrew. Twenty-four age-matched healthy women were taken as control cases. All were evaluated for electrolyte and acid-base balance-related parameters, bone turnover, markers and renal function. A significant decrease in net acid excretion was observed upon citrate supplementation, and this was paralleled by a significant decrease of urinary deoxypyridinolines, hydroxyproline-to-creatinine ratios, and, to a lesser extent, serum osteocalcin. Percent variations of urine citrate were inversely related to those of deoxypyridinolines and hydroxyproline. No change in these chemistries occurred in the control group. Our results suggest that treatment with an alkaline salt, such as potassium citrate, can reduce bone resorption thereby contrasting the potential adverse effects caused by chronic acidemia of protein-rich diets.
Subject(s)
Bone Density/drug effects , Bone Remodeling/drug effects , Bone Resorption/prevention & control , Osteoporosis, Postmenopausal/prevention & control , Potassium Citrate/pharmacology , Absorptiometry, Photon , Adult , Aged , Female , Femur/diagnostic imaging , Femur/drug effects , Femur/metabolism , Humans , Lumbar Vertebrae/diagnostic imaging , Lumbar Vertebrae/drug effects , Lumbar Vertebrae/metabolism , Middle Aged , Osteoporosis, Postmenopausal/blood , Potassium Citrate/therapeutic useABSTRACT
Risedronate treatment reduces the risk of vertebral fracture in women with existing vertebral fractures, but its efficacy in prevention of the first vertebral fracture in women with osteoporosis but without vertebral fractures has not been determined. We examined the risk of first vertebral fracture in postmenopausal women who were enrolled in four placebo-controlled clinical trials of risedronate and who had low lumbar spine bone mineral density (BMD) (mean T-score = -3.3) and no vertebral fractures at baseline. Subjects received risedronate 5 mg ( n = 328) or placebo ( n = 312) daily for up to 3 years; all subjects were given calcium (1000 mg daily), as well as vitamin D supplementation (up to 500 IU daily) if baseline serum 25-hydroxyvitamin D levels were low. The incidence of first vertebral fracture was 9.4% in the women treated with placebo and 2.6% in those treated with risedronate 5 mg (risk reduction of 75%, 95% confidence interval 37% to 90%; P = 0.002). The number of patients who would need to be treated to prevent one new vertebral fracture is 15. When subjects were stratified by age, similar significant reductions were observed in patients with a mean age of 64 years (risk reduction of 70%, 95% CI 8% to 90%; P = 0.030) and in those with a mean age of 76 years (risk reduction of 80%, 95% CI 7% to 96%; P = 0.024). Risedronate treatment therefore significantly reduces the risk of first vertebral fracture in postmenopausal women with osteoporosis, with a similar magnitude of effect early and late after the menopause.
Subject(s)
Calcium Channel Blockers/therapeutic use , Etidronic Acid/analogs & derivatives , Etidronic Acid/therapeutic use , Fractures, Bone/prevention & control , Osteoporosis, Postmenopausal/drug therapy , Aged , Bone Density , Calcium/administration & dosage , Female , Humans , Middle Aged , Risedronic Acid , Risk , Time Factors , Vitamin D/administration & dosageABSTRACT
OBJECTIVES: Pro-inflammatory cytokines mediate brain damage in multiple sclerosis (MS); they can also influence the hypothalamic-pituitary-adrenal (HPA) axis function. We evaluated the possible abnormalities of HPA axis function in relapsing-remitting MS (RR-MS). MATERIAL AND METHODS: IFN-gamma, TNF-alpha and IL-6 production by ex-vivo lymphocytes from 10 normal volunteers and 10 RR-MS patients before and during IFN-beta therapy was assessed; pituitary-adrenal function was evaluated by means of CRH and ACTH stimulation tests. RESULTS: In untreated patients the production of IFN-gamma, TNF-alpha, IL-6 was increased, and was significantly decreased by IFN-beta. Neither basal, nor stimulated ACTH, cortisol, DHEA, DHEAs, 17-alpha-OH-progesterone levels differed between controls and RR-MS patients, both before and during treatment. Moreover, no correlation was found between endocrine and immune parameters. CONCLUSION: In MS the HPA axis function seems normal and not influenced by IFN-beta treatment. This result is discussed in relation to the increased production of pro-inflammatory cytokines found in this disease.
Subject(s)
Adjuvants, Immunologic/therapeutic use , Hypothalamo-Hypophyseal System/metabolism , Hypothalamo-Hypophyseal System/physiopathology , Interferon-beta/therapeutic use , Interferon-gamma/metabolism , Interleukin-6/metabolism , Multiple Sclerosis , Pituitary-Adrenal System/metabolism , Pituitary-Adrenal System/physiopathology , Tumor Necrosis Factor-alpha/metabolism , Adult , Female , Humans , Male , Middle Aged , Multiple Sclerosis/drug therapy , Multiple Sclerosis/metabolism , Multiple Sclerosis/physiopathologyABSTRACT
The effects of a chronic treatment with corticosteroids on bone are well known, but few data are available regarding the acute effect of these drugs on bone turnover. This study was aimed at evaluating the effects of high doses of corticosteroids administered for a short period on bone metabolism. We assessed 23 subjects (15 women and 8 men) suffering from multiple sclerosis and treated with methylprednisolone (1 g i.v. for 10 days) followed by oral prednisone for 9 days; patients affected by diseases involving bone or treated during the previous 6 months with drugs influencing bone metabolism were excluded. We observed a significant decrease of ALP and bone glia protein (BGP), in these subjects, and a significant sudden increase of urinary calcium/creatinine and urinary cross-laps after 3 days of treatment. All of these parameters, except urinary calcium/creatinine, returned to basal levels after 30 days from the beginning of treatment (11 days after the interruption of corticosteroids administration). Serum phosphorus showed a significant decrease after 3 days of treatment, but returned to basal levels after 10 days. These data suggest that high doses of corticosteroids administered for a short period are able to induce an increase of bone resorption and a decrease of bone formation; moreover, bone turnover returns to basal levels when the treatment is stopped.
Subject(s)
Adrenal Cortex Hormones/administration & dosage , Adrenal Cortex Hormones/adverse effects , Bone Remodeling/drug effects , Adult , Alkaline Phosphatase/blood , Calcium/urine , Collagen/urine , Collagen Type I , Creatinine/urine , Female , Humans , Hydroxyproline/blood , Kinetics , Male , Multiple Sclerosis/drug therapy , Osteocalcin/blood , Peptides/urine , Phosphorus/bloodABSTRACT
One hundred ninety-eight postmenopausal women (aged 50-65 years) with vertebral bone density (VBD) 1 SD below the mean value for normal, age-matched, postmenopausal subjects were enrolled in six Italian centers and 134 completed 2 years of treatment. All subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d.) or a matching placebo, according to a double-blind, parallel group design. All patients also received an oral daily calcium supplement of 1 g as calcium carbonate. VBD and markers of bone turnover were measured at baseline, and every 6 months. A complete routine analysis of liver and kidney functions along with hematological parameters were measured before and at the end of treatment period. The valid completers analysis showed a significant increase of VBD in ipriflavone-treated women with average percent changes of +1.4 after 1 year, and +1% at the end of treatment period (P < 0.05). The placebo group presented a significant decrease of VBD after 2 years of treatment (P < 0.05). The difference between treatments was significant (P < 0.01). The intention to treat analysis confirmed the significant decrease of VBD in the placebo group, with no changes in ipriflavone-treated women. Skeletal ALP significantly decreased in ipriflavone-treated women (P < 0.05). Serum BGP and urine HOP/Cr showed a significant decrease only in ipriflavone-treated women, suggesting an inhibitory effect on bone turnover rate. Adverse reactions, mainly gastrointestinal, occurred to a similar extent in the two treatment groups. The evaluation of patients' compliance, assessed by residual tablets count, revealed a drug intake of more than 80% after 2 years in 92.5% and 92.8% of patients treated with ipriflavone or placebo, respectively. This study demonstrates that ipriflavone can prevent bone loss in postmenopausal women with low bone mass.
Subject(s)
Isoflavones/therapeutic use , Osteoporosis, Postmenopausal/prevention & control , Spinal Diseases/prevention & control , Aged , Bone Remodeling , Double-Blind Method , Female , Humans , Isoflavones/adverse effects , Middle Aged , Patient ComplianceABSTRACT
Two hundred and fifty-five postmenopausal women with distal forearm bone mineral density (BMD) 1 SD below the mean value for normal age-matched postmenopausal subjects were randomly allocated to a 2-year treatment with oral ipriflavone (200 mg t.i.d) or a matched placebo, according to a double-masked, parallel group design. All patients also received a 1 g/day calcium supplement. Distal radius BMD and bone metabolism markers were measured at baseline, and every 6 months. Blood haematology and chemistry and physical parameters were monitored at the same time. One hundred and ninety-six patients completed 2 years of treatment. BMD changes from baseline were analysed according to valid completers (VC) and intention to treat (ITT) analyses. In both cases radial BMD was maintained in patients treated with ipriflavone while in decrease in those receiving the placebo, the between-treatment difference being significant at year 1 and year 2. Urinary hydroxyproline/creatinine levels were decreased in the ipriflavone-treated group and increased in the placebo group, with a significant between-treatment difference. Adverse reactions, mainly gastrointestinal, occurred to a similar extent in the two treatment groups.
Subject(s)
Bone Density/drug effects , Isoflavones/therapeutic use , Osteoporosis, Postmenopausal/prevention & control , Radius/physiopathology , Aged , Bone and Bones/metabolism , Female , Humans , Hydroxyproline/urine , Isoflavones/adverse effects , Middle Aged , Osteoporosis, Postmenopausal/metabolism , Osteoporosis, Postmenopausal/physiopathologyABSTRACT
Recently it has been demonstrated that ipriflavone (IP), an isoflavone derivative, is able to increase bone mass in patients with established postmenopausal osteoporosis (PMO). Here we present a preliminary report of a 2-year multicenter, double-blind, placebo-controlled clinical study performed in order to evaluate the efficacy and tolerability of IP in PMO. A large number of patients with PMO, referred to 12 Italian centers, was randomly divided into 2 groups and treated with oral IP (600 mg/day) or placebo (Pl). All patients received an oral Ca supplement (1 g/day). One hundred and twenty six patients completed 1 year of the study. Bone mineral density (BMD) of the distal radius, measured by DPA, serum osteocalcin (BGP), and urinary hydroxyproline excretion (HOP/Cr), were measured before and after 12 months. After 12 months, a significant increase in BMD was observed in the IP-treated group (P < 0.05). IP determined a reduction of HOP/Cr, while in Pl-treated patients a significant increase of this index, as well as of BGP, was observed. After 12 months the difference between the two groups resulted significant (P < 0.05) for BGP. The drug was well tolerated and the patients' compliance to the oral treatment resulted excellent. The results of this study indicate that IP is able to increase bone mass in patients with PMO.
Subject(s)
Bone Density/drug effects , Calcium/metabolism , Isoflavones/therapeutic use , Osteoporosis, Postmenopausal/drug therapy , Aged , Double-Blind Method , Female , Humans , Isoflavones/administration & dosage , Isoflavones/pharmacology , Italy , Middle Aged , Osteoporosis, Postmenopausal/physiopathologyABSTRACT
The clinical use of calcium antagonist drugs in cardiology theoretically may interfere with the endocrine secretions. Actually the calcium ion appears to be primarily involved in the stimulus-secretion and excitation-contraction coupling. This paper is to evaluate the influence, in vivo, of nifedipine on calcium metabolism, FSH and LH secretions. The level of plasmatic calcium, parathyroid hormone (PTH), and FSH, LH secretion were observed in seven patients under cronic nifedipine treatment. The plasmic level of the hormones under investigation was tested with radioimmunoassay method. Neither calcium nor hormone levels had significant variations during the 28 days control period. From our data we can infer that long term treatment with nifedipine has no influence on calcium metabolism nor on gonadotropic hormones secretions, even though such an influence has been demonstrated in "in vivo" studies.
Subject(s)
Angina Pectoris/drug therapy , Calcium/metabolism , Gonadotropins, Pituitary/metabolism , Nifedipine/therapeutic use , Pyridines/therapeutic use , Female , Humans , Male , Middle Aged , Parathyroid Hormone/metabolismABSTRACT
A case of adenoma-based hyperparathyroidism operated at the 4th month of pregnancy (third reported case) is described. The clinical picture was extremely flimsy and diagnosis was formulated exclusively on the observation of the characteristic alterations in the calcium-phosphorus metabolism. The validity of examining renal phosphate excretion for the diagnosis of hyperparathyroidism is considered and proposed evaluation indices (P.E.I. of Nordin and Fraser; I.P.E. OF Nordin and Bulusu) are discussed. The gravity of foetal prognosis in hyperparathyroid women is sufficient justification for surgery during pregnancy.